Search

Displaying results 11 - 20 of 108 in total
  1. Indication

    Stage 3 Non-Small Cell Lung Carcinoma (NSCLC)

    go.drugbank.com/conditions/DBCOND0144292
    Drugs: Pembrolizumab
  2. Indication

    Unresectable Microsatellite Instability-High (MSI-H) Solid Tumors

    go.drugbank.com/conditions/DBCOND0144302
    Drugs: Pembrolizumab
  3. Indication

    Unresectable Mismatch repair deficient (dMMR) solid tumors

    go.drugbank.com/conditions/DBCOND0144305
    Drugs: Pembrolizumab
  4. Indication

    Metastatic Esophageal Carcinoma

    go.drugbank.com/conditions/DBCOND0120548
    Drugs: Pembrolizumab
  5. Indication

    Metastic Renal Cell Carcinoma

    go.drugbank.com/conditions/DBCOND0120572
    Drugs: Pembrolizumab
  6. Indication

    Stage IIC Melanoma

    go.drugbank.com/conditions/DBCOND0028888
    Drugs: Pembrolizumab
  7. Indication

    Stage IIIA Non-Small Cell Lung Cancer (NSCLC)

    go.drugbank.com/conditions/DBCOND0173421
    Drugs: Pembrolizumab
  8. Indication

    Locally advanced Adenocarcinomas of the Gastroesophageal Junction

    go.drugbank.com/conditions/DBCOND0144321
    Drugs: Pembrolizumab
  9. Indication

    Locally advanced Esophageal Carcinoma

    go.drugbank.com/conditions/DBCOND0144320
    Drugs: Pembrolizumab
  10. Indication

    Metastatic High Tumor Mutation Burden Solid Tumors

    go.drugbank.com/conditions/DBCOND0144327
    Drugs: Pembrolizumab